T umor-induced immune suppression is a major obstacle for therapies aimed at activating an individual's immune system to eliminate autologous cancer cells. Various mechanisms contribute to this immune suppression. A major contributor is the coinhibitory molecule programmed death ligand 1 (PDL1; also known as B7 homolog 1 [B7-H1] or CD274). PDL1 obstructs antitumor immunity by 1) tolerizing tumor-reactive T cells by binding to its receptor PD1 (CD279) on activated T cells (1, 2) ; 2) rendering tumor cells resistant to CD8 + T cell and Fas ligand-mediated lysis by PD1 signaling through tumor cell-expressed PDL1 (3); 3) tolerizing T cells by reverse signaling through T cell-expressed CD80 (4, 5) ; and 4) promoting the development and maintenance of induced T regulatory cells (6) .
Most malignant cells constitutively express or are induced by IFN-g to express PDL1 (1, 3, 7, 8) , and the loss of tumor suppressor genes can increase tumor cell expression of PDL1 (9) . Expression of PDL1 by human cancer cells is associated with de-creased patient survival time and a significant increase in overall patient mortality (10, 11) . Therefore, PDL1 is a major obstacle to natural antitumor immunity and to cancer immunotherapies requiring activation of host T cell-mediated antitumor immunity. This concept is supported by animal studies demonstrating that Ab blocking of PDL1-PD1 interactions improves T cell activation and reduces tumor progression (7, (12) (13) (14) (15) (16) , and that Ab blocking of PDL1 reverse signaling through T cell-expressed CD80 prevents T cell anergy (5) . Phase I/II clinical trials have indicated that PDL1-PD1 interactions are a major immune suppressive mechanism in cancer patients. Treatment with mAb to PD1 delays tumor progression in 18% of non-small cell lung cancer patients, 28% of melanoma patients, and 27% of renal cell cancer patients, whereas treatment with mAb to PDL1 delays tumor progression in 10% of advanced non-small cell lung cancer patients, 17% of melanoma patients, 12% of renal cell cancer patients, and 6% of ovarian cancer patients (17) (18) (19) . However, a majority of patients do not benefit from Ab therapy leading us to explore alternative strategies for inhibiting PDL1-PD1 interactions. On the basis of earlier reports that PDL1 also binds to CD80 (4, 20) , we hypothesized that coexpression of CD80 on PDL1 + tumor cells may prevent PDL1-PD1-mediated immune suppression (21) . We tested this hypothesis using PDL1 + human melanoma, breast cancer, and lung cancer cells transfected with membrane-bound human CD80 and observed that coexpression of CD80 prevented PD1 binding and restored T cell activation. Because in vivo transfection of cancer cells with membrane-bound CD80 is not clinically feasible, we have tested the ability of a soluble form of CD80 to restore T cell activation in the presence of PDL1 + human tumor cells. We now report that a soluble fusion protein consisting of human or mouse CD80 fused to the Fc region of human IgG1 (CD80-Fc) reverses PDL1-PD1mediated immune suppression by PDL1 + human or mouse tumor cells, respectively, and results in activation of CD4 + and CD8 + T lymphocytes. Comparison of CD80-Fc with Abs to PDL1 or PD1 suggests that CD80-Fc may be more effective than Ab therapy and that CD80-Fc mediates its effects by the dual mechanisms of inhibiting PDL1-PD1 interactions and by costimulating through CD28.
Materials and Methods

Cell lines, plasmids, and transfections
Human tumor cell lines MEL1011 and C8161 (cutaneous melanomas), MCF10CA1 (mammary carcinoma, hereafter called MCF10), H358 (bronchioloalveolar adenocarcinoma), H292 (squamous cell carcinoma), and murine tumor cell lines 4T1 (BALB/c-derived mammary carcinoma) and B16 MELF10 (C57BL/6-derived melanoma) were cultured as described previously (21) (22) (23) (24) . C8161/CD80, 4T1/CD80, and MELF10/CD80 transfectants were generated and maintained as described previously (21, 23, 25, 26) . COS cells were cultured in DMEM, supplemented with 10% heatinactivated FCS (Hyclone, Logan, UT), 1% penicillin/streptomycin (Bio-Source, Rockville, MD), 2 mM glutamax (Invitrogen Life Sciences, Grand Island, NY), 0.1% gentamicin (BioSource), and 5 mg/ml Prophylactic Plasmocin (InvivoGen, San Diego, CA) (27) . COS/PDL1/CD80 cells were made by transfecting COS cells with the pSNAP f vector (New England Biolabs, Ipswich, MA) containing PDL1, selecting for transfectants by culturing in 2 mg/ml G418, followed by transfection with pLHCX/CD80 (28) . The resulting COS/PDL1/CD80 cells were selected and maintained in media supplemented and 400 mg/ml hygromycin (Calbiochem).
Western blots
Western blots were performed as previously described (28) , except cellular extracts of plasma membrane fractions were prepared as follows: tumor cells were washed twice with sterile PBS, resuspended at 1 3 10 7 cells/800 ml PBS, homogenized using a GentleMACS Dissociator in GentleMACS M tubes (Miltenyi Biotec, Auburn, CA) using program Protein_01.01, and centrifuged at 13,690 3 g (Jouan, Winchester, VA) at 4˚C for 30 min. Supernatants containing the cytoplasmic proteins were discarded, 150 ml ice-cold lysis buffer was added to the pellets and the mixture incubated at 4˚C for 30 min on an Eppendorf Mixer (Eppendorf Mixer 5432). The resulting lysates were centrifuged at 13,690 3 g at 4˚C for 30 min, and the supernatants containing the membrane proteins were saved for subsequent electrophoresis. Membrane proteins (40 mg) were mixed with 5-ml sample buffer (0.5M Tris [pH 6.8], glycerol, 20% SDS, H 2 O, and bromophenol blue) for 30 min on an Eppendorf Mixer, centrifuged at 13,690 3 g at 4˚C for 30 min, and electrophoresed on 12% SDS-PAGE gels. The proteins were transferred to polyvinylidene difluoride membranes (Amersham Biosciences, Piscataway, NJ) using a Bio-Rad PowerPac HC (100 V for 70 min) and the membranes blocked with 5% nonfat dry milk in TBS and Tween 20 (TBST). PDL1 and b-actin were detected using 1 mg/ml PDL1 mAb (clone 5H1 (1)) and 0.05 mg/ml b-actin mAb, respectively, followed by 1:5000 dilution of sheep anti-mouse HRP (GE Healthcare Life Sciences, Pittsburgh, PA).
Mice
Breeding stock for BALB/c, BALB/c TCR transgenic DO11.10 (I-A drestricted, OVA peptide 323-339 specific), C57BL/6, C57BL/6 TCR transgenic OT-1 (H-2K b -restricted, OVA peptide 257-264 specific), and CD28 2/2 C57BL/6 mice were from The Jackson Laboratory. Mice were bred and maintained in the University of Maryland, Baltimore County (UMBC) animal facility. All animal procedures were approved by the UMBC Institutional Animal Care and Use Committee.
Abs, reagents, and flow cytometry
Human CD80-FITC (clone L307.4), mouse CD80-FITC (clone 16-10A1), mouse PDL1-PE (clone MIH5), human CTLA4-PE (clone BNI3), mouse IgG 1 -FITC (clone X40), rat IgG 2a -PE (clone R35-95), and hamster IgG-FITC (clone UC8-4B3) mAbs were from BD Biosciences. Human PDL1allophycocyanin (clone 29E.2A3), mouse PDL1-PE (clone 10F.9G2), human CD28-FITC (clone CD28.2), and rat IgG 2a -Alexa Fluor 647 (clone RTK2758) were from BioLegend (San Diego, CA). Mouse PDL1 (clone MIH6), mouse IgG 2b -allophycocyanin (clone eBMG2b), and rat IgG 2b -PE (clone TER-119) were from AbD Serotec (Raleigh, NC), eBioscience (San Diego, CA), and Caltag Laboratories (Burlingame, CA), respectively. Ionomycin was from EMD Millipore (Billerica, MA). PMA was from Sigma-Aldrich (St. Louis, MO). OVA 323-339 (ISQAVHAAHAEINEAGR) and OVA 257-264 (SIINFEKL) peptides were synthesized in the Biopolymer Core Facility at University of Maryland, Baltimore. Live cells were stained for cell surface expression and subjected to flow cytometry as previously described (28, 29) and analyzed using a Beckman Coulter Cyan ADP flow cytometer and Summit version 4.3.02 software.
Human PBMC activation
Cryopreserved PBMCs were obtained from healthy human donors as described previously (30) . PBMCs (6 3 10 4 ) and tumor cells (50 Gy irradiated, 3 3 10 4 ) were cocultured with 5 mg/ml PHA (Sigma-Aldrich) at 37˚C, 5% CO 2 for 72 h in a total volume of 200 ml/well T cell media (IMDM, 5% human AB serum, 2 mM glutamax, 1% penicillin/streptomycin, 1% gentamicin, 1% sodium pyruvate, 10 mM HEPES buffer, 5 3 10 25 M 2-ME, and 5 mg/ml prophylactic plasmocin) in 96-well plates. Soluble recombinant human CD80, CD86, PD1, and TROY (TNFR superfamily member), each fused to the Fc region of human IgG1 (CD80-Fc, CD86-Fc, PD1-Fc, and TROY-Fc, respectively [R&D Systems, Minneapolis, MN]), blocking mAbs PDL1 (clone 29E.2A3) and PD1 (clone EH12.2H7) (BioLegend), blocking mAb PDL1 (clone MIH1), PD1 (clone EH12.1), and PD1 (clone PD1.3.1.3) (eBioscience, Miltenyi Biotec, and BD Biosciences, respectively), and functional grade mouse IgG2b (clone eBMG2b) and IgG1 (clone P3.6.2.8.1) (eBioscience) were added to some wells at 10 mg/ml. Anti-CD28 (clone CD28.2; BioLegend) was used at 1-4 mg/ml. PBMCs were depleted of CD4 + and/or CD8 + T cells using CD4 and CD8 MicroBeads (Miltenyi Biotec), according to the manufacturer's directions. Molar equivalence of anti-CD28 and CD80-Fc: 0.01 mM anti-CD28 = 1.5 mg/ml; 0.01 mM CD80-Fc = 0.513 mg/ml. IFN-g production was measured by ELISA (30) .
IFN-g treatment and PD1-Fc binding
4T1 and 4T1/CD80 cells were incubated at 37˚C for 48 h in their culture medium supplemented with 100 U/ml recombinant mouse IFN-g (Pierce-Endogen, Rockford, IL) and washed with excess culture medium. Tumor cells were subsequently incubated in the presence or absence of mouse PDL1 (clone 43H12 (5)), followed by incubation with mouse PD1-Fc and anti-mouse mAb PD1-allophycocyanin (BioLegend). C8161 and C8161/ CD80 cells were incubated in the presence of human PD1-Fc, followed by anti-human PD1-allophycocyanin as described previously (21) .
Mouse splenocyte activation
Splenocytes from DO11.10 or OT-1 mice were depleted of RBCs, and incubated at 1 3 10 5 cells/well with 2 mg/well OVA 323-339 or OVA 257-264 peptide, respectively, in the presence of 2 3 10 5 irradiated (100 Gy) 4T1 or 4T1/CD80 cells, or irradiated (50 Gy) MELF10 or MELF10/CD80 cells, respectively, in the cells' culture medium at 37˚C, 5% CO 2 for 48 h in a total volume of 200 ml/well. Mouse CD80-Fc or mouse TROY-Fc was included in some wells at 10 mg/ml. IFN-g production was measured by ELISA (BioLegend). Splenocytes from CD28-deficient mice were depleted of RBCs and cultured at 37˚C, 5% CO 2 in 96-well plates at 1 3 10 5 cells/ well with 20 ng/ml PMA plus 1 mg/well ionomycin in the presence of irradiated MELF10 cells plus mouse TROY-Fc or CD80-Fc. IFN-g production was measured by ELISA (BioLegend).
Microscopy
Tumor cells were cultured in coverglass slides containing eight chambers (Thermo Scientific, Waltham, MA), washed with excess PBS containing 10% FCS, and labeled sequentially with mAb 5H1, anti-mouse IgG-Alexa Fluor 488 (Invitrogen, Grand Island, NY), and CD80-Alexa Fluor 647 (clone 2D10; BioLegend) (30 min each step, with PBS/FCS washes after each Ab). Following labeling, cells were fixed with formaldehyde, mounted in ProLong (Invitrogen), and imaged with a Leica TCS SP5 confocal microscope using Leica Application Suite Advanced Fluorescence software (Leica Microsystems, Buffalo Grove, IL).
Procedures with human materials were approved by the UMBC Institutional Review Board.
Statistical analysis
SD and Student t test were performed using Excel version 2008. Mann-Whitney U test was performed using http://faculty.vassar.edu/lowry/Vas-sarStats.html.
Results
CD80 prevents binding of some PDL1 mAb to CD80 + PDL1 + human tumor cells
We previously reported that PDL1 was not detected on the cell surface of CD80-transfected PDL1 + human tumor cells (21) . These studies used three anti-PDL1 mAbs (29E.2A3, MIH1, and 27A2) and raised the question of whether CD80 prevents expression or obstructs detection of cell surface PDL1. To resolve this issue, we used an additional anti-PDL1 mAb. C8161 and CD80-transfected C8161 (C8161/CD80) cells were stained for CD80 and PDL1 using the mAb 5H1 (1) and analyzed by flow cytometry (Fig. 1A) . In contrast to previous findings with the 29E.2A3, MIH1, and 27A2 mAbs, 5H1 mAb stained C8161/CD80 cells, indicating that CD80 does not inhibit cell surface expression of PDL1. To confirm that CD80 + cells contain cell surface PDL1, C8161 and C8161/CD80 cells were lysed, and the lysates were enriched for cell membranes and subjected to Western blotting with mAb 5H1 (Fig. 1B) . PDL1-Fc and C8161 cells served as positive controls. MEL1011, a PDL1 2 cell line, and TROY-Fc, an irrelevant soluble protein, were negative controls. C8161 and C8161/CD80 cells contain similar levels of membrane PDL1, confirming that CD80 does not obstruct cell surface expression of PDL1. mAbs 29E.2A3, MIH1, and 27A2 may have failed to detect PDL1 because they recognized epitopes that were sterically blocked by CD80. Tamada and colleagues have generated a rat anti-mouse PDL1 mAb (43H12) that prevents the binding of mouse CD80 to mouse PDL1 (5) . Because 5H1 detects PDL1 on PDL1 + CD80 + human cells, it may dissociate CD80-PDL1 interactions on human cells similarly to 43H12-mediated dissociation of PDL1 and CD80 on mouse cells. To test this possibility, C8161 and C8161/CD80 cells were either untreated or pretreated with 5H1 mAb prior to labeling with 29E.2A3 mAb (Fig. 1C ). As previously observed, 29E.2A3 did not detect PDL1 on C8161/CD80 cells. However, when C8161/CD80 cells were pretreated with 5H1 mAb, then PDL1 was detected by 29E.A3 mAb. In contrast, pretreatment with 5H1 did not result in subsequent binding of anti-PDL1 mAbs MIH1 or 27A2 (data not shown). To further examine CD80 and PDL1 coexpression, COS cells modified to stably express human PDL1 and human CD80 (COS/PDL1/CD80) were stained with mabs 5H1 and CD80 and analyzed by confocal microscopy (Fig. 1D ). COS/ PDL1/CD80 coexpressed CD80 and PDL1 on the cell surface. These results demonstrate that PDL1 is present on the cell surface of CD80 + human tumor cells and that some mAbs do not detect it because their binding sites are sterically obstructed by CD80.
Soluble CD80 restores activation of CD4 + and CD8 + T lymphocytes
Membrane-bound CD80 prevents PDL1-PD1-mediated immune suppression by human tumor cells (21) . However, introduction of membrane-bound CD80 into PDL1 + tumor cells is not an in vivo therapeutically feasible strategy. A soluble version of CD80 may have the same PDL1 binding properties as the membrane-bound form and therefore may also overcome PDL1 suppressive function. We first determined that activated human T cells express PD1 and are therefore susceptible to PDL1-mediated suppression and then tested whether the two extracellular domains of human CD80 fused to the Fc domain of human IgG1 (CD80-Fc) restored T cell activation in the presence of PDL1 + tumor cells.
To confirm that PHA activation induces PD1 expression, human PBMCs were cultured with PHA and tested for IFN-g production and expression of PD1 at 24, 48, and 72 h (Supplemental Fig. 1 ). Activated CD3 + CD4 + and CD3 + CD8 + T cells were identified by their expression of the activation marker CD45RO and by production of IFN-g. PD1 expression on activated T cells increased with time and in proportion to IFN-g production. These results indicate that PHA-activated T cells express PD1 and therefore should be susceptible to PDL1-mediated suppression.
To determine whether CD80-Fc restores T cell activation, PDL1 + C8161, MCF10, H292, and H358 cells ( Fig. 2A) were cocultured with allogeneic human PBMC plus PHA in the presence or absence of CD80-Fc or irrelevant TROY-Fc fusion protein. PBMC suppression was assessed by measuring IFN-g production (Fig.  2B) . PDL1 + C8161, MCF10, H292, and H358 cells suppressed IFN-g production by PHA-activated PBMCs and inclusion of CD80-Fc, but not TROY-Fc, restored IFN-g production.
To ascertain that the IFN-g-producing cells are T cells, PBMCs were depleted for CD4 + , CD8 + , or CD4 + plus CD8 + T cells prior to coculture with PDL1 + C8161 cells, PHA, and soluble fusion proteins (Fig. 2C ). CD80-Fc restored IFN-g production in undepleted cultures. Depletion of either CD8 + or CD4 + T cells reduced IFN-g production, and concomitant depletion of CD4 + plus CD8 + T cells eliminated IFN-g production. These results demonstrate that CD80-Fc restores activation of both CD4 + and CD8 + T cells.
Coexpression of CD80 and PDL1 on mouse tumor cells prevents PD1 binding
Our previous studies established that coexpression of human CD80 on PDL1 + human tumor cells prevented PD1 binding and PDL1mediated immune suppression (21) . To determine whether the same phenomenon occurred with murine cells, we used CD80 -4T1 mammary carcinoma cells and B16 MELF10 cells and their CD80 transfectants (4T1/CD80 and MELF10/CD80). As is the case for human tumor cells, some murine tumor cells constitutively express PDL1 and treatment with IFN-g increases PDL1 expression (31) . Mouse tumor cells were cultured with or without IFN-g and then stained and analyzed by flow cytometry for CD80 and PDL1 using mouse mAbs MIH5, 10F.9G2, and/or MIH6an (Fig. 3A , Supplemental Fig. 2 ). IFN-g upregulated cell surface PDL1 expression on all cells and all mAbs detected PDL1 on the CD80 transfectants. These results indicate that unlike human tumor cells, mAbs to mouse PDL1 predominantly react with epitopes outside of the mouse CD80-PDL1 binding region.
To determine whether coexpression of mouse CD80 restores T cell activation in the presence of PDL1 + mouse tumor cells, 4T1 and 4T1/CD80 tumor cells or MELF10 and MELF10/CD80 cells were cocultured with peptide-activated DO11.10 or OT-1 transgenic splenocytes, respectively, in the presence or absence of CD80-Fc or TROY-Fc (Fig. 3B ). PDL1 + parental 4T1 and MELF10 cells suppressed T cell activation and 4T1/CD80 cells, MELF10/ CD80 cells, and CD80-Fc restored T cell activation. These results demonstrate that similar to human PDL1 + tumors, CD80 restores T cell activation in the presence of PDL1 + murine tumor cells.
CD80 restores activation more effectively than mAb against PD1 or PDL1
Abs to PDL1 and PD1 delayed tumor progression and improved antitumor immunity in mice (32, 33) and have shown clinical efficacy in extending survival time of some patients with melanoma, non-small cell lung cancer, and renal cell carcinoma (18, 19) . To assess the relative activity of Abs versus CD80-Fc, human PBMCs were cocultured with PHA and C8161, H358, or H292 cells in the presence or absence of human CD80-Fc, TROY-Fc, or Ab to human PDL1 (mAb 29E.2A3) or human PD1 (mAb EH12.2H7) (Fig. 4) . As observed previously (Fig. 2B) , PDL1 + tumor cells suppressed T cell activation. CD80-Fc reversed the suppression and was more effective in reversing suppression than Abs to PDL1 or PD1. CD80- Fc was similarly more effective in reversing suppression as compared with other commonly used mAbs to PDL1 (MIH1 and 5H1), mAbs to PD1 (PD1.3.1.3 and EH12.1) (Supplemental Fig. 3A) , or human PD1-Fc (Supplemental Fig. 3B ).
CD80-Fc restores PBMC activation by both neutralizing PDL1-PD1 suppression and by costimulating
To determine whether coexpression of CD80 and PDL1 by human and mouse tumor cells prevents binding of PD1, human C8161 and C8161/CD80 cells were incubated with or without PD1-Fc, followed by anti-PD1-allophycocyanin (Fig. 5A ), or mouse 4T1 and 4T1/CD80 cells were treated with IFN-g and subsequently incu-bated with or without PD1-Fc, followed by staining with anti-PD1-allophycocyanin (Fig. 5B, top histograms) . Neither human (C8161/CD80) nor mouse (4T1/CD80) cells bound PD1-Fc, whereas FIGURE 3. Coexpression of membrane-bound CD80 on PDL1 + mouse tumor cells prevents binding of PD1. (A) CD80 + mouse tumor cells coexpress PDL1. Mouse 4T1 and CD80-transfected 4T1 (4T1/CD80) mammary carcinoma cells were cultured 6 IFN-g for 48 h and stained for PDL1 (mAb MIH5, 10F.9G2, and MIH6) and CD80 and analyzed by flow cytometry. (B) CD80-transfected PDL1 + murine tumor cells restore activation of Agactivated T cells. Splenocytes were isolated from DO11.10 or OT-1 transgenic mice and activated with their respective OVA peptide in the presence of 4T1 or 4T1/CD80, or MELF10 or MELF10/CD80 cells, respectively, with or without CD80-Fc or TROY-Fc. IFN-g production was measured by ELISA. Data are representative of three and two independent experiments for (A) and (B), respectively. the parental C8161 and 4T1 cells bound PD1-Fc, demonstrating that coexpression of CD80 prevents PD1 binding.
To confirm that mouse CD80 prevents mouse PD1 binding by interacting with PDL1, we used the PDL1 mAb 43H12, which dissociates mouse CD80-PDL1 complexes (5) . 4T1 and 4T1/CD80 cells were treated with IFN-g, followed by incubation with mAb 43H12, and subsequent staining with PD1-Fc and anti-PD1allophycocyanin (Fig. 5B, bottom histograms) . Cells treated with 43H12 bind PD1-Fc regardless of whether they express CD80, demonstrating that mouse CD80 prevents PD1-PDL1 interactions by binding to PDL1.
Our previous studies (21) and Fig. 5A and 5B establish that CD80 prevents PD1 binding to PDL1. However, CD80 may also promote T cell activation by delivering a costimulatory signal to T cells through CD28 (34, 35) . PHA-activated human T cells express CD28 (Supplemental Fig. 4A ), so they have the potential to be costimulated. To determine whether CD80-Fc also costimulates, we compared the ability of CD80-Fc versus Abs to CD28 to boost the response of PHA-activated human PBMCs in the absence of tumor cells. A single anti-CD28 Ab binds two CD28 molecules, whereas one CD80-Fc molecule binds only one CD28 molecule. To normalize binding capacity we compared the activity of two molar equivalents of CD80-Fc versus one molar equivalent of anti-CD28 mAb (Fig. 5C ). Abs to CD28 increased IFN-g production of PHA-activated human PBMCs by 38-42%, whereas equal binding units of CD80-Fc increased IFN-g production by only 14-28% (p , 0.0001). These results suggest that although CD80-Fc has some costimulatory activity, it is significantly less than anti-CD28 Abs, and its costimulatory activity is not sufficient to account for all of the restoration of T cell activation seen in Figs. 2-4 . Therefore, CD80 appears to restore T cell activation by concomitantly preventing PDL1-PD1 interactions and by costimulating.
To further examine the possibility that costimulation is involved, we compared T cell activation in the presence of CD80-Fc versus CD86-Fc because CD86 also costimulates via CD28 (36) and is three to five times more effective at costimulating than CD80 (37, 38) but does not bind PDL1 (4). If costimulation is involved, then CD86-Fc will also increase T cell activation. However, if CD80-Fc disrupts PDL1-PD1 interactions and costimulates, then CD80-Fc will be more effective than CD86-Fc in activating T cells. PHA-activated human PBMCs were cultured with or without human C8161 tumor cells in the presence of CD80-Fc, CD86-Fc, or control TROY-Fc (Fig. 5D ). CD80-Fc treatment produced more IFN-g as compared with CD86-Fc, indicating that CD80-Fc both costimulates and inhibits PDL1-PD1 interactions.
The results of Figs. 2-5 demonstrate that CD80-Fc mediates its effects by preventing PDL1-PD1 binding and by costimulating. FIGURE 5 . CD80-Fc restores PBMC activation by neutralizing PDL1-PD1 suppression and by costimulating through CD28. (A) Expression of CD80 prevents binding of PD1 to PDL1 + tumor cells. C8161 and C8161/ CD80 human tumor cells were incubated with or without recombinant human PD1-Fc fusion protein, followed by staining with mAb to PD1 and analyzed by flow cytometry. (B) 4T1 and 4T1/CD80 mouse tumor cells were cultured with IFN-g for 48 h, followed by incubation 6 unlabeled PDL1 mAb 43H12, which disrupts PDL1-CD80 interactions. Tumor cells were subsequently incubated with recombinant mouse PD1-Fc, followed by staining with mAb to PD1, and analyzed by flow cytometry. (C) CD80-Fc has less costimulatory activity than Abs to CD28. Healthy donor PBMCs were activated with PHA and cultured with CD80-Fc or Abs to CD28. IFN-g production was measured by ELISA. Molar concentration for Ab was one-half the molar concentration of CD80-Fc to compensate for each Ab molecule binding two molecules of CD28 versus each CD80-Fc molecule binding only one molecule of CD28. (D) CD80-Fc restores PBMC activation more effectively than CD86-Fc. PHA-activated PBMCs from healthy donors were cocultured with or without C8161 human tumor cells in the presence or absence of CD80-Fc, CD86-Fc, or TROY-Fc. IFNg production was measured by ELISA. (E) Splenocytes from CD28 2/2 mice were activated with PMA and ionomycin and cocultured with MELF10 mouse tumor cells 6 CD80-Fc, CD86-Fc, or TROY-Fc. Data are representative of three, three, three, three, and two independent experiments for (A), (B), (C), (D), and (E), respectively. However, these data do not determine whether costimulation is obligatory for the PDL1-PD1 inhibitory function of CD80-Fc. To assess this possibility, PMA plus ionomycin-activated splenocytes from MHC syngeneic CD28 knockout mice were cocultured with murine MELF10 tumor cells in the presence or absence of CD80-Fc, CD86-Fc, or control TROY-Fc (Fig. 5E ). CD28 2/2 splenocytes were suppressed by MELF10 cells, and the suppression was not reversed by either CD80-Fc or CD86-Fc, indicating that costimulation through CD28 is integral to the ability of CD80-Fc to block PDL1-PD1 interactions.
CD80-Fc may also restore T cell activation by binding to T cell-expressed PDL1
A potential drawback to using CD80-Fc as a reagent to inhibit PDL1-PD1 interactions is its potential to suppress T cell activation by binding to T cell-expressed CTLA4 (39, 40) . In the experiments presented in this study, CD80-Fc increases, rather than decreases, T cell production of IFN-g (see Fig. 2 ), making it unlikely that CD80-Fc is interacting with CTLA4. However, the lack of suppression in our experiments could be due to the absence of CTLA4 on PHA-activated T cells. To test this possibility, human PBMCs were activated for 72 h with PHA and subsequently stained for CD3 and CTLA4 (Supplemental Fig. 4B ). Thirty percent of PHA-activated PBMCs were CD3 + CTLA4 + . Therefore, PHA-activated T cells are potentially susceptible to CTLA4-mediated immune suppression; however, CD80-Fc does not appear to induce suppression via CTLA4.
Sixty-five percent of PHA-activated PBMC express PDL1 (Supplemental Fig. 4C ), giving rise to the possibility that CD80-Fc may not only inhibit tumor cell PDL1-mediated suppression but also neutralize PDL1-PD1 suppression caused by activated T cells.
Discussion
We previously reported that coexpression of membrane-bound CD80 on PDL1 + human tumor cells prevents PDL1-PD1-mediated immune suppression and restores activation of human T cells (21) . The present report extends these findings to murine tumor cells and importantly demonstrates that a soluble form of the extracellular domains of CD80 (CD80-Fc) similarly counteracts PDL1-PD1-mediated T cell apoptosis. CD80-Fc appears to be more effective than Abs to either PDL1 or PD1 in preventing PDL1-mediated immune suppression, thus suggesting that CD80-Fc is a potentially useful therapeutic agent for enhancing antitumor immunity in cancer patients.
In addition to binding to PDL1, CD80 also binds to CTLA4 (40, 41) . Therefore, soluble CD80 has the potential to cause T cell anergy by interacting with T cell-expressed CTLA4 (42) . Although PHA-activated T cells express CTLA4, it is unlikely that soluble CD80 suppresses via CTLA4 because of the robust T cell activation observed. The absence of CTLA4-mediated suppression could be because PDL1 and CTLA4 share a common binding region on CD80 so that CD80 binding to PDL1 sterically prevents CTLA4 binding. This possibility is supported by cross-linking studies indicating that murine PDL1 and CTLA4 interact with CD80 at overlapping sites (4). However, we have generated CD80 mutants that do not bind CTLA4 but retain the ability to bind PDL1 (data not shown), suggesting that PDL1 and CTLA4 do not share a common binding site on CD80. It is also unlikely that the lack of suppression via CTLA4 is due to preferential binding of CD80 to PDL1 versus CTLA4 because human CD80 and CTLA4 interact more strongly (K D = 0.4 mM) than human CD80 and PDL1 (K D = ∼1.4 mM) (4).
CD80-Fc maintains T cell activation in the presence of PDL1 + tumor cells by simultaneously preventing PDL1-PD1 interactions and by providing costimulation. PD1 binding studies demonstrate that CD80 prevents PD1 binding to both mouse and human PDL1 + tumor cells, whereas experiments with anti-CD28 Abs and CD28deficient mice demonstrate that costimulation also occurs. It is unlikely that this costimulatory activity will result in autoimmunity to self-Ags because human CD80 binds PDL1 more tightly than it binds CD28 (K D = ∼1.4 versus 4 mM, respectively) (4). In addition, we have observed that 65% of PHA-activated PBMCs express PDL1, raising the possibility that CD80-Fc could also prevent PDL1-PD1 interactions between PDL1 + and PD1 + PBMCs.
In our previous studies, we did not detect PDL1 on CD80 + human tumor cells using three anti-PDL1 mAbs (21) . Two of these Abs (29E.2A3 and MIH1) were previously reported to recognize epitopes in the PDL1-CD80 binding region (20) , whereas the binding site of the third Ab (27A2) was unknown. However, pretreatment with mAb 5H1, which dissociates PDL1-CD80 interactions (5) , allows binding of anti-PDL1 mAb 29E.2A3 but not anti-PDL1 mAb MIH1 or 27A2. These observations confirm that mAb 29E.2A3 reacts with an epitope on PDL1 within the PDL1-CD80 binding region that is revealed by CD80-PDL1 dissociation. The absence of binding of mAb MIH1 and 27A2 following treatment with mAb 5H1 suggests that mAb 5H1 only partially dissociates CD80-PDL1 interactions and that the epitopes detected by mAb MIH1 and 27A2 remain blocked by CD80.
It is surprising that CD80-Fc is more effective than mAb to PDL1 or PD1 in preventing PDL1-PD1-mediated suppression. Given that the binding constants of Abs for PDL1 or PD1 are typically several orders of magnitude stronger than that of soluble CD80 to PDL1, one would expect Abs to be more effective in blocking PDL1-PD1 interactions. Structural studies (4, 20) and our results are consistent with the concept that soluble CD80 prevents PDL1-PD1 interactions by steric blocking, and Abs to PDL1 and PD1 are thought to act in a similar fashion. It is likely that CD80-Fc is more effective than Abs because CD80-Fc costimulates in addition to perturbing PDL1-PD1 binding. Therefore, CD80-Fc may be a more efficacious therapeutic than mAbs to PDL1 and/or PD1. If CD80-Fc and Abs restore T cell activation via independent or partially overlapping mechanisms, then these two reagents may be additive or synergistic and their combined application could be more efficacious than either reagent alone. In either case, CD80-Fc may provide a new approach for reversing immune suppression and facilitating antitumor immunity in individuals with cancer.
